Recipharm to Lead Kinnovata in Bringing the Clickhaler to China
Recipharm will manufacture the Asmasal Clickhaler for Kinnovata and the Chinese market following regulatory approval from the CFDA.
Recipharm will manufacture the Asmasal Clickhaler for Kinnovata and the Chinese market following regulatory approval from the CFDA.
Packaging specialist Contract Pharmaceutical Services of Australia (CPSA) has received a warning letter from the US FDA due to humidity control violations on products distributed in the US.
BD says its new quality by design glass prefillable syringe offers added safety in delivering biologics as the industry continues to shift toward biotechnology.
AstraZeneca has announced its second bolt-on acquisition in as many months, unveiling a $1.5bn move for respiratory drug developer Pearl Therapeutics.
AstraZeneca has chosen ePharmaSolutions to provide IT services for three separate neuroscience trials.
The Japanese joint venture between Dr. Reddy’s and Fujifilm has been called-off though both say future collaboration remains likely, especially in API production.
Epidemiological and other medical research could be prohibitively difficult to conduct if a new European regulation is passed, according to three professors from the University of Amsterdam.